Austraian company Dimerix has announced an agreement with UK-based Advanz Pharma to commercialise DMX-200 for a major kidney disease in the European Economic Area, the UK, Switzerland, Canada, Australia, and New Zealand. …
Australian company Dimerix enters agreement to commercialise DMX-200 in major markets
October 6, 2023 Latest NewsBioPharmaAustralian Biotech
Latest Video
New Stories
-
Argent BioPharma advances epilepsy strategy with CannPal acquisition
April 13, 2026 - -
Telix signs new cancer development deal with Regeneron
April 13, 2026 - - Australian Biotech -
Australia risks falling further behind on access to new medicines without action, industry warns
April 13, 2026 - - Latest News -
HTA Review timeline set to extend well into the second half of 2027
April 13, 2026 - - Latest News -
The endpoint now coming into view was, in truth, always the most likely one
April 12, 2026 - - Latest News -
Cartherics and Catalent deepen partnership to accelerate next generation cell therapies
April 10, 2026 - - Australian Biotech -
Lower official co-payment but patients paying for more unsubsidised medicines
April 10, 2026 - - Latest News